Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 9
1995 34
1996 32
1997 48
1998 41
1999 56
2000 52
2001 28
2002 33
2003 28
2004 34
2005 39
2006 19
2007 24
2008 30
2009 30
2010 25
2011 33
2012 30
2013 31
2014 33
2015 40
2016 38
2017 39
2018 32
2019 52
2020 61
2021 62
2022 53
2023 59
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

1,063 results

Results by year

Filters applied: . Clear all
Page 1
3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
Tovar-Parra D, Gil-Quiñones SR, Nova J, Gutiérrez-Castañeda LD. Tovar-Parra D, et al. In Vivo. 2021 May-Jun;35(3):1529-1536. doi: 10.21873/invivo.12406. In Vivo. 2021. PMID: 33910831 Free PMC article.
BACKGROUND/AIM: Genetic variations of the CDKN2A and CDK4 gene have been associated to melanoma development. ...MATERIALS AND METHODS: DNA was extracted from whole blood samples from 85 patients diagnosed with cutaneous melanoma and 166 healthy controls. CDKN2A …
BACKGROUND/AIM: Genetic variations of the CDKN2A and CDK4 gene have been associated to melanoma development. ...MATERIALS AND …
Germline mutations predisposing to melanoma.
Toussi A, Mans N, Welborn J, Kiuru M. Toussi A, et al. J Cutan Pathol. 2020 Jul;47(7):606-616. doi: 10.1111/cup.13689. Epub 2020 May 11. J Cutan Pathol. 2020. PMID: 32249949 Free PMC article. Review.
Nearly 15% of melanomas occur in patients with a family history and a subset of these patients have a germline mutation in a melanoma predisposing gene. CDKN2A mutations are responsible for the majority of hereditary melanoma, but many other susceptibility genes hav …
Nearly 15% of melanomas occur in patients with a family history and a subset of these patients have a germline mutation in a melanoma predis …
Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma.
Kreuger IZM, Slieker RC, van Groningen T, van Doorn R. Kreuger IZM, et al. J Invest Dermatol. 2023 Jan;143(1):18-25.e1. doi: 10.1016/j.jid.2022.07.016. Epub 2022 Sep 16. J Invest Dermatol. 2023. PMID: 36123181 Free article. Review.
Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event driving melanoma progression. Therefore, therapeutic strategies aimed at CDKN2A loss hold great potential to improve melanoma treatment. Pharmacological inhibition of the p …
Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event driving melanoma progression. Therefore, t …
CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
Karagianni F, Njauw CN, Kypreou KP, Stergiopoulou A, Plaka M, Polydorou D, Chasapi V, Pappas L, Stratigos IA, Champsas G, Panagiotou P, Gogas H, Evangelou E, Tsao H, Stratigos AJ, Stefanaki I. Karagianni F, et al. Acta Derm Venereol. 2018 Oct 10;98(9):862-866. doi: 10.2340/00015555-2969. Acta Derm Venereol. 2018. PMID: 29774366 Free PMC article.
Approximately 5-10% of melanoma cases occur in a familial context. CDKN2A/CDK4 were the first high-penetrance melanoma genes identified. ...A cross-sectional study was conducted by genotyping CDKN2A/CDK4 variants and selected MC1R polymorphisms …
Approximately 5-10% of melanoma cases occur in a familial context. CDKN2A/CDK4 were the first high-penetrance melanoma gene …
Clinical histopathological features and CDKN2A/CDK4/MITF mutational status of patients with multiple primary melanomas from Bologna: Italy is a fascinating but complex mosaic.
Dika E, Patrizi A, Rossi C, Turchetti D, Miccoli S, Ferracin M, Veronesi G, Scarfì F, Lambertini M. Dika E, et al. Ital J Dermatol Venerol. 2021 Oct;156(5):599-605. doi: 10.23736/S2784-8671.20.06496-2. Epub 2020 Mar 27. Ital J Dermatol Venerol. 2021. PMID: 32221274
The aim was to investigate the rate of multiple cMs (MPM), assessing their clinical/pathological features. Moreover, the genetic tests of patients who had undergone CDKN2A/CDKN2B, CDK4 and MITF screening were evaluated. RESULTS: One hundred fifteen patients (9.26%) …
The aim was to investigate the rate of multiple cMs (MPM), assessing their clinical/pathological features. Moreover, the genetic tests of pa …
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Martin-Broto J, Martinez-Garcia J, Moura DS, Redondo A, Gutierrez A, Lopez-Pousa A, Martinez-Trufero J, Sevilla I, Diaz-Beveridge R, Solis-Hernandez MP, Carnero A, Perez M, Marcilla D, Garcia-Foncillas J, Romero P, Fernandez-Jara J, Lopez-Lopez D, Arribas I, Hindi N. Martin-Broto J, et al. Signal Transduct Target Ther. 2023 Oct 25;8(1):405. doi: 10.1038/s41392-023-01661-8. Signal Transduct Target Ther. 2023. PMID: 37875500 Free PMC article. Clinical Trial.
Preclinical investigators of this study found that CDK4 overexpression, while not of CDKN2A, was the most consistent predictive factor for palbociclib efficacy in sarcomas. ...Translational research showed a significant correlation between CDK4 mRNA and prote …
Preclinical investigators of this study found that CDK4 overexpression, while not of CDKN2A, was the most consistent predictiv …
CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Newton Bishop JA, Taylor C, Debniak T, Lubinski J, Kleina R, Heisele O. Pjanova D, et al. Melanoma Res. 2007 Jun;17(3):185-91. doi: 10.1097/CMR.0b013e328014a2cd. Melanoma Res. 2007. PMID: 17505264
Germline mutations of the CDKN2A and CDK4 genes explain a significant proportion of familial melanoma. ...CDKN2A polymorphisms were studied as putative low penetrance susceptibility genes. ...
Germline mutations of the CDKN2A and CDK4 genes explain a significant proportion of familial melanoma. ...CDKN2A …
CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM, Raspé E, Coulonval K, Decaussin-Petrucci M, Tarabichi M, Dom G, Libert F, Craciun L, Andry G, Wicquart L, Leteurtre E, Trésallet C, Marlow LA, Copland JA, Durante C, Maenhaut C, Cavaco BM, Dumont JE, Costante G, Roger PP. Pita JM, et al. Front Endocrinol (Lausanne). 2023 Oct 26;14:1247542. doi: 10.3389/fendo.2023.1247542. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37964967 Free PMC article.
Tumors and cell lines without phosphorylated CDK4 presented very high p16(CDKN2A) levels, which were associated with proliferative activity. ...Moreover, the complementary use of our 11 genes predictor with p16/KI67 evaluation could represent a …
Tumors and cell lines without phosphorylated CDK4 presented very high p16(CDKN2A) levels, which were associated with pr …
Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel E 3rd, Baldwin N, Jhunjhunwala S, Nickles D, Assaf ZJ, Bower D, Patil N, McCleland M, Shames D, Molinero L, Huseni M, Sanjabi S, Cummings C, Mellman I, Mariathasan S, Hegde P, Powles T. Banchereau R, et al. Nat Commun. 2021 Jun 25;12(1):3969. doi: 10.1038/s41467-021-24112-w. Nat Commun. 2021. PMID: 34172722 Free PMC article. Clinical Trial.
At the pathway level, significant heterogeneity is observed between indications, in particular within the PD-L1(+) tumors. mUC and NSCLC are molecularly aligned, with cell cycle and DNA damage repair genes associated with response in PD-L1- tumors. At the gene level, the …
At the pathway level, significant heterogeneity is observed between indications, in particular within the PD-L1(+) tumors. mUC and NSCLC are …
Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma.
Nikolaou V, Kang X, Stratigos A, Gogas H, Latorre MC, Gabree M, Plaka M, Njauw CN, Kypreou K, Mirmigi I, Stefanaki I, Tsao H. Nikolaou V, et al. Br J Dermatol. 2011 Dec;165(6):1219-22. doi: 10.1111/j.1365-2133.2011.10551.x. Epub 2011 Nov 2. Br J Dermatol. 2011. PMID: 21801156 Free PMC article.
The frequency of mutations increases with the number of family members affected and the number of primary tumours, and also fluctuates with geography. To date, little is known about the prevalence of CDKN2A mutations in patients with melanoma from Greece. OBJECTIVE: To cha …
The frequency of mutations increases with the number of family members affected and the number of primary tumours, and also fluctuates with …
1,063 results